After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute (NCI) for the past 5 years, says that he will resign his post in April of this year. He will join IVAX Corporation (Miami), a manufacturer of generic drugs and IV drug delivery devices, where he plans to work on developing new drugs.
WASHINGTON--Samuel Broder, MD, head of the National Cancer Institute(NCI) for the past 5 years, says that he will resign his postin April of this year. He will join IVAX Corporation (Miami),a manufacturer of generic drugs and IV drug delivery devices,where he plans to work on developing new drugs.
Dr. Broder first joined the NCI in 1972 as a researcher. He wasthe leader of a group that discovered the therapeutic benefitsof the antiretroviral agent zidovudine (Retrovir, AZT) in 1985.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
